Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Biomarkers of Parkinson's disease: present and future. Metabolism (2014) 1.14

Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol (2014) 1.00

Moving stem cells to the clinic: potential and limitations for brain repair. Neuron (2015) 0.94

Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease. Drug Des Devel Ther (2015) 0.78

Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol (2017) 0.78

Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's disease. PLoS One (2017) 0.77

Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future. Transl Neurodegener (2015) 0.77

Looking beyond the brain to improve the pathogenic understanding of Parkinson's disease: implications of whole transcriptome profiling of Patients' skin. BMC Neurol (2017) 0.75

Editorial: Neurotherapeutics of movement disorders. Neurotherapeutics (2014) 0.75

Effects of a combination treatment of KD5040 and L-dopa in a mouse model of Parkinson's disease. BMC Complement Altern Med (2017) 0.75

Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. BMC Neurol (2015) 0.75

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist. Curr Neuropharmacol (2016) 0.75

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52

Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51

Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A (1981) 8.45

Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science (1989) 7.03

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord (2003) 6.94

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76

Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science (2012) 6.66

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21

A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81

A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81

Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49

Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med (2010) 5.27

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99

Selegiline as initial treatment in de novo parkinsonian patients. Neurology (1992) 4.75

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med (2003) 4.51

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol (2011) 4.23

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA (2000) 4.10

Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03

LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med (2006) 3.90

Genetic animal models of Parkinson's disease. Neuron (2010) 3.86

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84

Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. Arch Neurol (2005) 3.78

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology (2007) 3.62

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Ann Neurol (2005) 3.58

Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J Neurosci (2001) 3.55

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA (2002) 3.46

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med (1993) 3.40

Gout and risk of Parkinson disease: a prospective study. Neurology (2007) 3.09

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol (2001) 3.09

Plasma urate and risk of Parkinson's disease. Am J Epidemiol (2007) 3.06

The role of radiotracer imaging in Parkinson disease. Neurology (2005) 3.02

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology (2006) 3.01

Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med (1989) 2.97

Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord (2009) 2.96

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90

Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84

Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell (2012) 2.83

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79

The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78

Serum uric acid levels and the risk of Parkinson disease. Ann Neurol (2005) 2.47

Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg (2002) 2.45

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44

Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol (2007) 2.36

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol (2004) 2.34

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology (2007) 2.32

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) 2.29

Lower low-density lipoprotein cholesterol levels are associated with Parkinson's disease. Mov Disord (2007) 2.24

Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun (1989) 2.23

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17

Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14

Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann Neurol (2003) 2.14

Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2011) 2.12

Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol (2001) 2.11

Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol (2004) 2.11

Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10

The functional role of the subthalamic nucleus in cognitive and limbic circuits. Prog Neurobiol (2005) 1.99

TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2006) 1.95

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov Disord (2010) 1.72

Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med (2007) 1.72

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70

Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol (2008) 1.69

A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68

Deep brain stimulation for Parkinson's disease: disrupting the disruption. Lancet Neurol (2002) 1.67

Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56

G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol (2005) 1.54

Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord (2012) 1.49

Serum cholesterol levels and the risk of Parkinson's disease. Am J Epidemiol (2006) 1.49

Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett (2003) 1.46

Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol (2000) 1.45

α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42

α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med (2012) 1.40

Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J Comp Neurol (1987) 1.39

Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol (1999) 1.37

Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol (1994) 1.36

Mitophagy and Parkinson's disease: the PINK1-parkin link. Biochim Biophys Acta (2010) 1.34

Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol (2007) 1.34

Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest (2013) 1.32

Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat Med (1997) 1.30

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res (2001) 1.29

Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol (2011) 1.29

The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol (1995) 1.29

Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat (2001) 1.28

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol (1996) 1.28

NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Trends Pharmacol Sci (1995) 1.22

Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol (1998) 1.22

Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett (1999) 1.21

Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease. Neurology (2006) 1.21

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet (2011) 1.21

Biomarkers and Parkinson's disease. Brain (2004) 1.17

Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76

Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98

Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77

From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77

Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56

Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86

Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66

Src kinases: a hub for NMDA receptor regulation. Nat Rev Neurosci (2004) 3.65

Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22

Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15

Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10

Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07

Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93

Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79

Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67

A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64

Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53

Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46

Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40

Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32

Glycine binding primes NMDA receptor internalization. Nature (2003) 2.30

Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23

Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21

Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20

Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19

Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18

Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18

Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11

Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med (2011) 2.05

Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02

Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01

Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00

Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99

A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98

Tyrosine phosphatase STEP is a tonic brake on induction of long-term potentiation. Neuron (2002) 1.95

Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91

Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86

Neto1 is a novel CUB-domain NMDA receptor-interacting protein required for synaptic plasticity and learning. PLoS Biol (2009) 1.85

Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82

Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82

Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81

Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81

Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79

Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77

Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73

Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70

Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66

Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63

Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63

Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63

Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63

Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62

Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60

Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59

Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58

Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54

Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54

Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54

Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53

Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease. Proc Natl Acad Sci U S A (2014) 1.53

Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53

Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51

Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47

Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46

Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46

Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45

Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45

Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45

The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43

α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42

Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord (2013) 1.42

Subthalamic nucleus stimulation: improvements in outcome with reprogramming. Arch Neurol (2006) 1.42

Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol (2002) 1.40

Reporting clinical trials: full access to all of the data. Arch Neurol (2002) 1.39

Definition and classification of hyperkinetic movements in childhood. Mov Disord (2010) 1.38

Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol (2002) 1.36

Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol (2006) 1.34

Investigation of c9orf72 in 4 neurodegenerative disorders. Arch Neurol (2012) 1.32

Gait abnormalities in psychogenic movement disorders. Mov Disord (2007) 1.32

Cortical and spinal abnormalities in psychogenic dystonia. Ann Neurol (2006) 1.31

Apraxia in movement disorders. Brain (2005) 1.29

The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway. Hum Mol Genet (2004) 1.29

Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol (2004) 1.28

The nonmotor symptoms of Parkinson's disease--an overview. Mov Disord (2010) 1.25

Movement disorders on YouTube--caveat spectator. N Engl J Med (2011) 1.25

The many faces of corticobasal degeneration. Parkinsonism Relat Disord (2007) 1.22

The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21

Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord (2003) 1.19

Crossroads in GDNF therapy for Parkinson's disease. Mov Disord (2006) 1.19

Involvement of the cerebellothalamocortical pathway in Parkinson disease. Ann Neurol (2010) 1.16

Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch Neurol (2004) 1.14